AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year
CHICAGO, Sept. 7, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, achieved the top biotech industry sector ranking on the Dow Jones Sustainability Index (DJSI). Since AbbVie's founding in 2013, the company has been listed on both DJSI World and DJSI North America every year. DJSI is a leading global benchmark of 3,900 companies based on environmental, social and governance practices.
AbbVie earned the highest overall score among 40 biotechnology companies and led the industry on 13 of 25 criteria. In two categories, Environmental Reporting and Policy Influence, AbbVie scored a perfect 100. The company's Labor Practice Indicators and Human Capital Development scores showed the greatest increases from 2016, both increasing by more than 15 points.
"Our commitment to innovation goes beyond medicine, to the larger impact our actions make on society," said Richard A. Gonzalez, chairman of the board and chief executive officer, AbbVie. "As a patient-driven company, we believe strong research must be paired with a strong commitment to the communities we serve. We are grateful to DJSI for this recognition, and will continue our ongoing efforts to improve sustainability."
AbbVie's corporate responsibility commitments are to improve health outcomes, operate responsibly and contribute to communities. More information about programs and impacts of these corporate responsibility commitments is available at www.AbbVie.com/Responsibility.
About Dow Jones Sustainability Indices
This annual review is published by S&P Dow Jones Indices (S&P DJI), one of the world's leading index providers, and RobecoSAM, the investment specialist focused exclusively on sustainability investing. Launched in 1999, the DJSI World is the gold standard for corporate sustainability and the first global index to track the leading sustainability-driven companies based on RobecoSAM's analysis of financially relevant Environmental, Social, and Governance (ESG) factors and S&P DJI's robust index methodology. RobecoSAM invited the world's largest 3,900 companies from developed and emerging markets to take part in its annual Corporate Sustainability Assessment. For more information, please visit www.sustainability-indices.com.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Mary Kathryn Steel
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Before engaging, please read and adhere to our established community guidelines for each channel.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
You must be logged in to view this item.
This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.